Delafloxacin as a New Therapeutic Tool for the Treatment of Skin and Soft Tissue Infections: Experience in a Single Center

Delafloxacin, a fluoroquinolone, has activity against a broad range of Gram-positive and Gram-negative bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA), and is effective in acidic environments, such as infected tissues. The aim of this study is to report the experience with Delafloxacin for the treatment of skin and soft tissue infections in a hospital in São Paulo, as well as to create a database of patients who have used the drug.This retrospective study included 36 patients with skin and soft tissue infections, assessing clinical and laboratory parameters before and after 72 hours of treatment.The results showed significant improvements in laboratory parameters: reductions in leukocyte count, C-reactive protein (CRP) levels, and creatinine, along with an increase in estimated glomerular filtration rate (eGFR). The average duration of treatment was 8.7 days, with adverse effects occurring in only 5.5% of patients (delirium and diarrhea). The 30-day readmission rate was 11.1%, with 5.5% related to infectious causes. These findings align with previous studies indicating delafloxacin’s effectiveness for complicated skin infections, demonstrating good tolerability and potential for reducing bacterial resistance due to its unique mechanism of action.The study concludes that delafloxacin is an effective and safe therapeutic option, especially in elderly patients with comorbidities, and highlights the need for continuous monitoring given the readmission rate and the complexity of the patients treated.ImportanceThe publication of this article is justified by its contribution to clinical practice, reporting the use of delafloxacin for skin and soft tissue infections in a Brazilian hospital. Unlike controlled clinical trials, this study provides real-world data on efficacy and safety, particularly in elderly patients with comorbidities.Findings demonstrate significant improvements in inflammatory and renal parameters, a low incidence of adverse events, and a favorable safety profile. Additionally, the analysis of readmission rates offers a more comprehensive assessment of the therapy.The study also highlights delafloxacin’s potential in reducing bacterial resistance, a crucial factor in antibiotic selection. The establishment of a patient database may support future research. Given the Brazilian context and the scarcity of local data, this publication will aid clinical decision-making and promote the rational use of antibiotics.